Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachael L Sumner

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Psychopharmacology|September 5, 2024
Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamideRobin J Murphy, Rachael L Sumner, Kate Godfrey, et al.
Human Brain Mapping|April 18, 2018
Peak visual gamma frequency is modified across the healthy menstrual cycleRachael L Sumner, Rebecca L McMillan, Alexander D Shaw, et al.
Frontiers in Neuroendocrinology|January 4, 2024
Electroencephalography findings in menstrually-related mood disorders: A critical reviewElisavet Kaltsouni, Felix Schmidt, Rachel G Zsido, et al.
Neuroimage|July 26, 2020
Generative modelling of the thalamo-cortical circuit mechanisms underlying the neurophysiological effects of ketamineAlexander D Shaw, Suresh D Muthukumaraswamy, Neeraj Saxena, et al.
Trials|September 29, 2022
A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorderJulia R Plank, Stephanie C Glover, Ben D Moloney, et al.
Trials|February 12, 2020
A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorderJoseph C C Chen, Rachael L Sumner, Venkat Krishnamurthy Naga, et al.
Frontiers in Pharmacology|March 23, 2026
Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm studyBen D Moloney, Anna Forsyth, Rachael L Sumner, et al.
Trials|April 24, 2021
MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteersRobin J Murphy, Rachael L Sumner, William Evans, et al.
Therapeutic Advances in Psychopharmacology|December 9, 2025
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trialCarina Joy Donegan, Dimitri Daldegan-Bueno, Rachael L Sumner, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 9, 2020
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errorsRachael L Sumner, Rebecca McMillan, Meg J Spriggs, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Psychopharmacology|September 5, 2024
Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamideRobin J Murphy, Rachael L Sumner, Kate Godfrey, et al.
Human Brain Mapping|April 18, 2018
Peak visual gamma frequency is modified across the healthy menstrual cycleRachael L Sumner, Rebecca L McMillan, Alexander D Shaw, et al.
Frontiers in Neuroendocrinology|January 4, 2024
Electroencephalography findings in menstrually-related mood disorders: A critical reviewElisavet Kaltsouni, Felix Schmidt, Rachel G Zsido, et al.
Neuroimage|July 26, 2020
Generative modelling of the thalamo-cortical circuit mechanisms underlying the neurophysiological effects of ketamineAlexander D Shaw, Suresh D Muthukumaraswamy, Neeraj Saxena, et al.
Trials|September 29, 2022
A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorderJulia R Plank, Stephanie C Glover, Ben D Moloney, et al.
Trials|February 12, 2020
A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorderJoseph C C Chen, Rachael L Sumner, Venkat Krishnamurthy Naga, et al.
Frontiers in Pharmacology|March 23, 2026
Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm studyBen D Moloney, Anna Forsyth, Rachael L Sumner, et al.
Trials|April 24, 2021
MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteersRobin J Murphy, Rachael L Sumner, William Evans, et al.
Therapeutic Advances in Psychopharmacology|December 9, 2025
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trialCarina Joy Donegan, Dimitri Daldegan-Bueno, Rachael L Sumner, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 9, 2020
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errorsRachael L Sumner, Rebecca McMillan, Meg J Spriggs, et al.
Pageof 3